Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

parafarm pty ltd - tylosin tartrate - oral powder, pre-mix - tylosin tartrate antibiotic active 850.0 mg/g - antibiotic & related - poultry | turkeys | breeder | breeders | broiler | broiler breeder | chickens | chicks | chooks | day old chicks | hatchlings | - antibiotic - anti-infective | abrasions | abscesses | airsacculitis | antiseptic | avian mycoplasmas | blackhead | body odours | bowed tendons | broad spectrum | burns | coccidiosis | coliform complex | conjunctivitis | cowpox | cracks | crusts | dandruff | dermatological disorders | dermatosis | dry skin | dysentery | eczema | endometritis | enteric diseases | enzootic pneumonia | feed efficiency | fungal infections | girth galls | infections | inflammed pads | itching | keratolytic | lacerations | mastitis | mycoplasmas | odours | open wounds | otitis | pruritis | queensland itch | respiratory disease | saddle rash | salmonellosis | scabs | scaly skin | sheath rot | skin irritations | sores | swine dysentery | teat cracking | teat infections | topical infections | udder sores | weight gain | wire cuts | wounds

Australia - English - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - thiamine hydrochloride, quantity: 100 mg/ml - injection - excipient ingredients: disodium edetate; benzyl alcohol; water for injections - thiamine hydrochloride injection is used for the prevention and treatment of vitamin b1 deficiency.

United States - English - NLM (National Library of Medicine)

a-s medication solutions - nortriptyline hydrochloride (unii: 00fn6ih15d) (nortriptyline - unii:bl03sy4lxb) - nortriptyline 25 mg - nortriptyline hydrochloride is indicated for the relief of symptoms of depression. endogenous depressions are more likely to be alleviated than are other depressive states. the use of maois intended to treat psychiatric disorders with nortriptyline hydrochloride or within 14 days of stopping treatment with nortriptyline hydrochloride is contraindicated because of an increased risk of serotonin syndrome. the use of nortriptyline hydrochloride within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated (see  warnings and dosage and administration ). starting nortriptyline hydrochloride in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see  warnings  and  dosage and administration ). cross-sensitivity between nortriptyline hydrochloride and other dibenzazepines is a possibility. nortriptyline hydrochloride is contraindicated during the acute recovery period after myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - folic acid, quantity: 5 mg/ml - injection - excipient ingredients: water for injections; sodium hydroxide; disodium edetate - 1. megaloblastic anaemia where the anaemia has been proven to be due to folate deficiency only. 2. prevention of folic acid deficiency in pregnancy and lactation.

Australia - English - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - folic acid, quantity: 15 mg/ml - injection, solution - excipient ingredients: water for injections; sodium hydroxide; disodium edetate - 1. megaloblastic anaemia where the anaemia has been proven to be due to folate deficiency only. 2. prevention of folic acid deficiency in pregnancy and lactation.

Australia - English - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - thiamine hydrochloride, quantity: 5 mg/ml; riboflavine sodium phosphate, quantity: 2.5 mg/ml; nicotinamide, quantity: 50 mg/ml; dexpanthenol, quantity: 10 mg/ml; pyridoxine hydrochloride, quantity: 25 mg/ml - injection, solution - excipient ingredients: disodium edetate; water for injections - b vitamin deficiencies may exist that are unable to be corrected by oral intake and in these cases parenteral administration may be preferable. oral administration of b vitamins may be insufficient in; alcoholism, pernicious anaemia, malabsorption disorders, gastrectomy, gastrointestinal pathologies and debilitated and elderly patients. specific indications include: 1. rapid saturation of the b group vitamins. 2. when oral administration is not feasible or appropriate. 3. for alcoholic, debilitated and elderly patients when their diet is inadequate. 4. patients requiring parenteral b vitamin therapy who cannot tolerate intramuscular injections. 5. recovery from beriberi and wernicke's syndrome as a result of vitamin b1 deficiency. please note that iv b-dose 2ml injection does not contain sufficient thiamine for acute treatment of wernicke's syndrome. 6. pellagra as a result of vitamin b3 deficiency. patients with pellagra may have a concurrent deficiency of b1, b2 and b6. 7. peripheral neuritis caused by vari

Australia - English - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - thiamine hydrochloride, quantity: 100 mg/ml; riboflavine sodium phosphate, quantity: 2 mg/ml; nicotinamide, quantity: 20 mg/ml; dexpanthenol, quantity: 20 mg/ml; pyridoxine hydrochloride, quantity: 40 mg/ml; cyanocobalamin, quantity: 0.4 mg/ml - injection, solution - excipient ingredients: disodium edetate; benzyl alcohol; water for injections - b vitamin deficiencies may exist that are unable to be corrected by oral intake and in these cases parenteral administration may be preferable. oral administration of b vitamins may be insufficient in; alcoholism, pernicious anaemia, malabsorption disorders, gastrectomy, gastrointestinal pathologies and debilitated and elderly patients. specific indications include: 1. rapid saturation of the b group vitamins. 2. when oral administration is not feasible or appropriate. 3. for alcoholic, debilitated and elderly patients when their diet is inadequate. 4. beriberi and wernicke's syndrome as a result of vitamin b1 deficiency. 5. pellagra as a result of vitamin b3 deficiency. patients with pellagra may have a concurrent deficiency of b1, b2, b6 and b12. 6. peripheral neuritis caused by various b group deficiencies. 7. carpal tunnel syndrome. 8. pernicious anaemia as a result of in situ b12 deficiency. general indications include: 1. angular stomatitis and glossitis have been shown in some instances to respond to t

Australia - English - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - thiamine hydrochloride, quantity: 10 mg/ml; riboflavine sodium phosphate, quantity: 2.5 mg/ml; pyridoxine hydrochloride, quantity: 5 mg/ml; dexpanthenol, quantity: 2.5 mg/ml; nicotinamide, quantity: 25 mg/ml; cyanocobalamin, quantity: 0.5 mg/ml - injection, solution - excipient ingredients: water for injections - b vitamin deficiencies may exist that are unable to be corrected by oral intake and in these cases parenteral administration may be preferable. oral administration of b vitamins may be insufficient in; alcoholism, pernicious anaemia, malabsorption disorders, gastrectomy, gastrointestinal pathologies and debilitated and elderly patients. commonly, several b vitamin deficiencies may occur similtaneously. specific indications include: 1. rapid saturation of the b group vitamins. 2. when oral administration is not feasible or appropriate. 3. for alcoholic, debilitated and elderly patients when their diet is inadequate. 4. recovery from beriberi and wernicke's syndrome as a result of vitamin b1 deficiency. please note that b-dose 2ml injection does not contain sufficient thiamine for acute treatment of wernicke's syndrome. 5. pellagra as a result of vitamin b3 deficiency. patients with pellagra may have a concurrent deficiency of b1, b2, b6 and b12. 6. peripheral neuritis caused by various b group deficiencies. 7.

United States - English - NLM (National Library of Medicine)

unit dose services - nortriptyline hydrochloride (unii: 00fn6ih15d) (nortriptyline - unii:bl03sy4lxb) - nortriptyline 25 mg - nortriptyline hydrochloride is indicated for the relief of symptoms of depression. endogenous depressions are more likely to be alleviated than are other depressive states. the use of maois intended to treat psychiatric disorders with nortriptyline hydrochloride or within 14 days of stopping treatment with nortriptyline hydrochloride is contraindicated because of an increased risk of serotonin syndrome. the use of nortriptyline hydrochloride within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated (see warnings and dosage and administration ). starting nortriptyline hydrochloride in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see warnings and dosage and administration ). cross-sensitivity between nortriptyline hydrochloride and other dibenzazepines is a possibility. nortriptyline hydrochloride is contraindicated during the acute recovery period

Australia - English - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - sodium ascorbate, quantity: 300 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections - sodium ascorbate solution injection for intravenous infusion is indicated for the treatment of vitamin c deficiency when oral treatment is not feasible.